Lindsey Finney

A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors

Johanna C. Bendell, Carla Kurkjian, Jeffrey R. Infante et al. · Investigational New Drugs · 2015 · 115 citations

Pharmacy, Oncology, Pharmacology +8

Paclitaxel/carboplatin with or without sorafenib in the first‐line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute

John D. Hainsworth, Dana S. Thompson, John A. Bismayer et al. · Cancer Medicine · 2014 · 58 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC).

Erika Hamilton, Ololade Dosunmu, Mythili Shastry et al. · Journal of Clinical Oncology · 2023 · 20 citations

Medicine, Oncology, Pharmacology +16

Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non–small cell lung cancer: A randomized, placebo‐controlled phase 2 trial with correlated serum proteomic signatures

David R. Spigel, Howard A. Burris, F. Anthony Greco et al. · Cancer · 2018 · 15 citations · Full text

Medicine, Oncology, Pharmacology +15

Cabazitaxel Plus Lapatinib as Therapy for HER2+ Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study

Denise A. Yardley, Lowell L. Hart, Patrick J. Ward et al. · Clinical Breast Cancer · 2018 · 14 citations

Medicine, Oncology, Pharmacology +17